In vitro growth suppression of vascular smooth muscle cells using adenovirus-mediated gene transfer of a truncated form of fibroblast growth factor receptor

Atherosclerosis

Volumn 141, Issue 1, 1998, Pages 125-132

  Yukawa, Hiroyuki ^a   Miyatake, Shin Ichi ^a   Saiki, Masaaki ^a   Takahashi, Jun C ^a   Mima, Tatsuo ^b   Ueno, Hikaru ^c   Nagata, Izumi ^d   Kikuchi, Haruhiko ^d   Hashimoto, Nobuo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Adenovirus; Fibroblast growth factor receptor; Gene therapy; Vascular smooth muscle cell

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CELL PROLIFERATION; GENE THERAPY; GENE TRANSFER; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MUSCLE CELL; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RAT; RESTENOSIS; VASCULAR SMOOTH MUSCLE;

ADENOVIRIDAE; ANIMALS; ARTERIOSCLEROSIS; BLOTTING, WESTERN; CELL DIVISION; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 0032487564     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00162-2     Document Type: Article

References (48)

1. Zierler R.E., Bandyk D.F., Thiele B.L., Strandness Jr D.E. Carotid artery stenosis following endarterectomy. Arch. Surg. 117(11):1982;1408-1415.
2. Ross R. The Pathogenesis of atherosclerosis: an update. N. Engl. J. Med. 314:1986;488-500.
3. Leimgruber P.P., Roubin G.S., Hollman J., Cotsonis G.A., Meiter B., Douglas J.S. et al. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation. 73:1986;710-717.
4. Gruentzig A.R., King S.B., Schlumpf M., Siegenthaler W. Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. N. Engl. J. Med. 316:1987;1127-1132.
5. Becker G.J., Katzen B.T., Dake M.D. Noncoronary angioplasty. Radiology. 170:1989;921-940.
6. Touho H. Percutaneous transluminal angioplasty in the treatment of atherosclerotic disease of the anterior cerebral circulation and hemodynamic evaluation. J. Neurosurg. 82(6):1995;953-960.
7. Ferns G.A.A., Raines E.W., Sprugel K.H., Motani A.S., Reidy M.A., Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 253:1991;1129-1132.
8. Lindner V., Reidy M.A. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA. 88(9):1991;3739-3743.
9. Epstein S.E., Siegall C.B., Biro S., Fu Y.M., Fitzgerald D., Pastan I. Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells. Circulation. 84:1991;778-787.
10. Simons M., Edelman E.R., DeKayser J.L., Langer R., Rosenberg R.D. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 359:1992;67-70.
11. Biro S., Siegall C.B., Fu Y.M., Speir E., Pastan I., Epstein S.E. In vitro effects of a recombinant toxin targeted to the FGF receptor on rat vascular smooth muscle and endothelial cells. Circ. Res. 71:1992;640-645.
12. Casscells W., Lappi D.A., Olwin B.B., Wai C., Siegman M., Speir E. et al. Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors. Proc. Natl. Acad. Sci. USA. 89:1992;7159-7163.
13. Speir E., Epstein S.E. Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the mRNA encoding PCNA. Circulation. 86:1992;538-547.
14. Simons M., Rosenberg R.D. Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ. Res. 70:1992;835-843.
15. Biro S., Fu Y.M., Yu Z.X., Epstein S.E. Inhibitory effects of antisense ologonucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc. Natl. Acad. Sci. USA. 90:1993;654-658.
16. Morishita R., Gibbons G.H., Ellison K.E., Nakajima M., Zhang L., Kaneda Y. et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA. 90:1993;8474-8478.
17. Ohno T., Gordon D., San H., Pompili V.J., Imperiale M.J., Nabel G.J. et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 265(5173):1994;781-784.
18. Gospodarowicz D., Ferrara N., Schweigerer L., Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr. Rev. 8(2):1987;95-114.
19. Gospodarowicz D., Neufeld G., Schweigerer L. Fibroblast growth factor. Mol. Cell. Endocrinol. 46(3):1986;187-204.
20. Goldfarb M. The fibroblast growth factor family. Cell. Growth. Differ. 1(9):1990;439-445.
21. Raines E.W., Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br. Heart. J. 69(Suppl 1):1993;S30-S37.
22. Ferns G.A., Stewart Lee A.L., Anggard E.E. Arterial response to mechanical injury: balloon catheter de-endothelialization. Atherosclerosis. 92(2-3):1992;89-104.
23. Fox J.C., Shanley J.R. Antisense inhibition of basic fibroblast growth factor induces apoptosis in vascular smooth muscle cells. J. Biol. Chem. 271(21):1996;12578-12584.
24. Hanna A.K., Fox J.C., Neschis D.G., Safford S.D., Swain J.L., Golden M.A. Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J. Vasc. Surg. 25(2):1997;320-325.
25. Ueno H., Gunn M., Dell K., Tseng Jr A., Williams L. A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor. J. Biol. Chem. 267(3):1992;1470-1476.
26. Miyake S., Makimura M., Kanegae Y., Harada S., Sato Y., Takamori K. et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc. Natl. Acad. Sci. USA. 93(3):1996;1320-1324.
27. Mima T., Ueno H., Fischman D.A., Williams L.T., Mikawa T. Fibroblast growth factor receptor is required for in vivo cardiac myocyte proliferation at early embryonic stages of heart development. Proc. Natl. Acad. Sci. USA. 92(2):1995;467-471.
28. Kanegae Y., Lee G., Sato Y., Tanaka M., Nakai M., Sakaki T. et al. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic. Acids. Res. 23(19):1995;3816-3821.
29. Saito I., Oya Y., Yamamoto K., Yuasa T., Shimojo H. Construction of nondefective adenovirus type 5 bearing a 2.8-kilobase hepatitis B virus DNA near the right end of its genome. J. Virol. 54(3):1985;711-719.
30. Kanegae Y., Makimura M., Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn. J. Med. Sci. Biol. 47(3):1994;157-166.
31. Chamley J.H., Campbell G.R., McConnell J.D., Groschel Stewart U. Comparison of vascular smooth muscle cells from adult human, monkey and rabbit in primary culture and in subculture. Cell. Tissue. Res. 177(4):1977;503-522.
32. Hanneken A., Maher P.A., Baird A. High affinity immunoreactive FGF receptors in the extracellular matrix of vascular endothelial cells-Implications for the modulation of FGF-2. J. Cell. Biol. 128(6):1995;1221-1228.
33. Pan X., Arauz E., Krzanowski J.J., Fitzpatrick D.F., Polson J.B. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem. Pharmacol. 48(4):1994;827-835.
34. Gospodarowicz D., Ferrara N., Haaparanta T., Neufeld G. Basic fibroblast growth factor: expression in cultured bovine vascular smooth muscle cells. Eur. J. Cell. Biol. 46(1):1988;144-151.
35. Lindner V., Lappi D.A., Baird A., Majack R.A., Reidy M.A. Role of basic fibroblast growth factor in vascular lesion formation. Circ. Res. 68(1):1991;106-113.
36. Olson N.E., Chao C., Lindner V., Reidy M. Intimal smooth muscle cell proliferation after balloon catheter injury; The role of basic fibroblast growth factor. Am. J. Pathol. 140:1992;1017-1023.
37. Stratford-Perricaudet L.D., levrero M., Chasse J., Perricaudet M., Briand P. Evaluation of the transfer and expression in mice of an enzyme-coding gene using a human adenovirus vector. Hum. Gene. Ther. 1:1990;241-256.
38. Quantin B., Perricaudet L.D., Tajbakhsh S., Mandel J. Adenovirus as an expression vector in muscle cells in vivo. Proc. Natl. Acad. Sci. USA. 89:1992;2581-2584.
39. Lemarchand P., Jones M., Yamada I., Crystal R.G. In vivo gene transfer and expression in normal, uninjured vessels using replication-deficient recombinant adenovirus vectors. Circ. Res. 5:1993;1132-1138.
40. Guzman R.J., Lemarchand P., Crystal R.G., Epstein S.E., Finkel T. Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation. 88(6):1993;2838-2848.
41. Guzman R.J., Hirschowitz E.A., Brody S.L., Crystal R.G., Epstein S.E., Finkel T. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. USA. 91(22):1994;10732-10736.
42. Chang M.W., Barr E., Lu M.M., Barton K., Leiden J.M. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. 96(5):1995;2260-2268.
43. Ueno H., Yamamoto H., Ito S., Li J.J., Takeshita A. Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arterioscler. Thromb. Vasc. Biol. 17(5):1997;898-904.
44. Chang M.W., Barr E., Seltzer J., Jiang Y.Q., Nabel G.J., Nabel E.G. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 267(5197):1995;518-522.
45. Wu K.K. Prostacyclin and nitric oxide-related gene transfer in preventing arterial thrombosis and restenosis. Agents. Actions. Suppl. 48:1997;107-123.
46. Yang Y., Nunes F.A., Berencsi K., Furth E.E., Gonczol E., Wilson J.M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA. 91(10):1994;4407-4411.
47. Johnston C.L., Cox H.C., Gomm J.J., Coomnes R.C. Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments A splice variant of FGFR-3 localizes to the nucleus. J. Biol. Chem. 270(51):1995;30643-30650.
48. Maher P.A. Nuclear Translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. J. Cell. Biol. 134(2):1996;529-536.